XRCC1 and ADPRT Polymorphisms Associated with Survival in Breast Cancer Cases Treated with Chemotherapy

• DOI: 10.7314/apjcp.2012.13.10.4923
• Publication Date: 2013-02-22T07:57:41Z
• Authors: Sheng Ye; Jian Rong; Shao-Hong Huang; Zhou-San Zheng; Miao Yun; Shen-Ming Wang
• Keywords: Polymorphism, Genetic; Poly (ADP-Ribose) Polymerase-1; Breast Neoplasms; Middle Aged; Prognosis; Polymerase Chain Reaction; 3. Good health; DNA-Binding Proteins; 03 medical and health sciences; 0302 clinical medicine; Doxorubicin; Antineoplastic Combined Chemotherapy Protocols; Humans; Female; Genetic Predisposition to Disease; Fluorouracil; Prospective Studies; Poly(ADP-ribose) Polymerases; Cyclophosphamide; Polymorphism, Restriction Fragment Length; Epirubicin; Follow-Up Studies; Neoplasm Staging

To investigate whether XRCC1 and ADPRT polymorphisms might be associated with outcomes of breast cancer.A prospective study was conducted with a total of 335 breast cancer patients undergoing chemotherapy consecutively collected from Jan. 2005 to Jan. 2008. Genotyping of XRCC1 and ADPRT polymorphisms was conducted by PCR-RFLP assay.All 335 patients were followed up until death or the end of Jan. 2012, with a median follow-up period of 38.8 (2-64) months. It was shown that the variant genotype of XRCC1 399Gln/Gln was strongly significantly associated with a decreased risk of death from breast cancer, with an HR (95% CI) of 0.52 (0.28-0.91). Similarly, individuals carrying the ADPRT 762Ala/Ala demonstrated longer survival compared to ADPRT 762 Val/ Val, with an HR (95% CI) of 0.58 (0.31-0.97). Individuals with combination genotypes of XRCC1 399Gln allele and ADPRT 762Ala/Ala presented with a longer survival, the HR (95% CI) being 0.56 (0.32-0.97).We found a significant association between XRCC1399Gln/ Gln and ADPRT 762Ala/Ala polymorphisms and clinical outcomes. These two genotypes could be used as a surrogate markers of clinical outcome in glioma cases receiving chemotherapy.